KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non-Current Deffered Revenue (2016 - 2022)

Jazz Pharmaceuticals (JAZZ) has 13 years of Non-Current Deffered Revenue data on record, last reported at $116000.0 in Q3 2022.

  • For Q3 2022, Non-Current Deffered Revenue fell 88.24% year-over-year to $116000.0; the TTM value through Sep 2022 reached $116000.0, down 88.24%, while the annual FY2021 figure was $463000.0, 80.0% down from the prior year.
  • Non-Current Deffered Revenue reached $116000.0 in Q3 2022 per JAZZ's latest filing, down from $231000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $13.6 million in Q1 2018 and bottomed at $116000.0 in Q3 2022.
  • Average Non-Current Deffered Revenue over 5 years is $4.4 million, with a median of $3.3 million recorded in 2020.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 38.41% in 2019, then tumbled 88.24% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $9.6 million in 2018, then plummeted by 49.26% to $4.9 million in 2019, then crashed by 52.38% to $2.3 million in 2020, then tumbled by 80.0% to $463000.0 in 2021, then tumbled by 74.95% to $116000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $116000.0 in Q3 2022, $231000.0 in Q2 2022, and $347000.0 in Q1 2022.